Clinical trials: Small Bowel Bacterial Overgrowth
Small Intestinal Bacterial Overgrowth
Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth
Study Synopsis This pilot study will determine the efficacy of a novel supplement protocol and low FODMAP diet for the treatment of small intestinal bacterial overgrowth (SIBO).
- Trial name
- NCT03420976
- Testing
- Novel Supplement Based Therapy
- Where
- United States
- Sponsor
- Atrium Innovations
HIV, Non-HIV
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
The study team's prior research has shown that dysfunction of a specific nerve, called the vagus nerve, is associated with small intestinal bacterial overgrowth (SIBO), and that SIBO is associated with signs of inflammation in…
- Conditions
- HIV, Non-HIV, Vagus Nerve Dysfunction
- Trial name
- EVA (NCT04353778)
- Testing
- Pyridostigmine, non-invasive vagal nerve stimulation
- Where
- United States
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
SIBO, Pancreatic Insufficiency
Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy
Pancreatic exocrine insufficiency (PEI) results from reduced pancreatic enzyme secretion, leading to malabsorption, malnutrition, and impaired quality of life.
- Conditions
- SIBO, Pancreatic Insufficiency, Chronic Pancreatitis, Pancreatic Surgey
- Trial name
- DCP-PCT-EPI (NCT07479238)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Small Intestinal Bacterial Overgrowth (SIBO)
Botanical Blend on the Gut Microbiome and Gut-Skin-Axis in Small Intestinal Bacterial Overgrowth (SIBO)
The purpose of this study is to assess how an oral botanical blend alters the gut microbiome and the skin biophysical properties in people with SIBO.
- Trial name
- NCT04867512
- Testing
- Liquid Tincture, GI Detox, Olivirex
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Gulf War Digestive Health Study
The purposes of this study are to estimate the burden of disease due to chronic gastrointestinal illness in PG veterans, to evaluate whether Small Bowel Bacterial Overgrowth (SBBO) is associated with chronic diarrhea in PG…
- Trial name
- NCT00680836
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- US Department of Veterans Affairs
Small Intestinal Bacterial Overgrowth
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
- Trial name
- NCT06298409
- Testing
- CapScan collection capsule
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Envivo Bio Inc
Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases
Transit Time and Bacterial Overgrowth Using SmartPill Capsule
The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test.
- Conditions
- Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
- Trial name
- NCT00577772
- Testing
- Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Obesity and Overweight
Kombucha in Overweight and Obese: Live Vs. Pasteurized Effects on Microbiota, Metabolism, and Liver Function
Kombucha, a fermented beverage made from Camellia sinensis tea (black, oolong, or green) with sugar and a symbiotic culture of bacteria and yeast (SCOBY), has gained global attention for its potential health benefits.
- Trial name
- KOMBIOME (NCT06759324)
- Testing
- Live kombucha (non filtered/ non pasteurized), Pasteurized kombucha (non filtered), Control (sparkling water)
- Where
- 2 sites in Portugal
- Volunteers
- 33 people
- Sponsor
- Associação Centro de Apoio Tecnológico Agro Alimentar
Small Intestinal Bacterial Overgrowth
Methane and Hydrogen Breath Test for the Diagnosis of Small Intestinal Bacterial Overgrowth
To investigate whether the positive rates of methane and hydrogen breath test were different between the experimental group and the control group.
- Trial name
- NCT06483360
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Abdominal Distention, Abdominal Bloating
Clinical Characteristics of Small Intestinal Bacterial Overgrowth in Individuals With Abdominal Bloating/Distention
Abdominal bloating/distention represents a prevalent clinical manifestation characterized by an unclear etiology and pathogenesis.
- Trial name
- NCT06285734
- Testing
- Breath test
- Where
- China
- Volunteers
- 387 people
- Sponsor
- Shandong University
Periodontitis (Stage 3), Periodontitis Stage IV
Characterization of Small Intestinal Bacterial Overgrowth and Intestinal Barrier-Related Biomarkers in Patients With Severe Periodontitis: A Pilot Prospective Longitudinal Observational Cohort Study
Periodontitis is a chronic inflammatory disease characterized by dysbiotic subgingival biofilms, inflammation, and progressive destruction of the tooth-supporting tissues.
- Conditions
- Periodontitis (Stage 3), Periodontitis Stage IV, SIBO
- Trial name
- MIRA (NCT07907224)
- Where
- Romania
- Volunteers
- 20 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Decompensated Cirrhosis, Small Bowel Bacterial Overgrowth Syndrome
Primary Prophylaxis for Spontaneous Bacterial Peritonitis
Patient with liver cirrhosis commonly have co-existing small bowel bacterial overgrowth (SIBO) yet may be asymptomatic. It is unclear as to the value of treating SIBO in asymptomatic individuals.
- Trial name
- SIBOC (NCT04775329)
- Testing
- Rifaximin
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Changi General Hospital
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS
Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial
Small intestinal bacterial overgrowth (SIBO) is a common condition associated with gastrointestinal symptoms such as bloating, abdominal pain, diarrhea, and constipation, particularly in patients with irritable bowel syndrome.
- Trial name
- SIBO-Probiotic (NCT07426705)
- Testing
- Probiotic preparation, Rifaximin (drug)
- Volunteers
- 100 people
- Sponsor
- Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Small Intestinal Bacterial Overgrowth
A Trial of a Multi-Component Nutritional Supplement in Hydrogen-Dominant Small Intestinal Bacterial Overgrowth
The goal of this trial is to evaluate the safety and tolerability of an 8-week, multi-component nutritional supplement (AV1PD1A) in adults with hydrogen-dominant small intestinal bacterial overgrowth (SIBO).
- Trial name
- AV1-SIBO (NCT07215676)
- Testing
- AV1PD1A
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National University of Natural Medicine
Small Intestine Bacterial Overgrowth
Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension
Most studies of bloating have focused on functional factors, while data on organic abdominal distention are rare, and studies that combine small intestine bacterial overgrowth and/or oral cecum transit time abnormalities are more…
- Trial name
- NCT06518850
- Testing
- Rifaximin
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Liver Cirrhosis, Ascites
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
This investigational trial will be assessing the effect of rifaximin on pathophysiology and haemodynamics in the patient with liver cirrhosis, and addressing the effect of rifaximin on several organs on marker level.
- Trial name
- NCT01769040
- Testing
- Rifaximin
- Where
- Denmark
- Volunteers
- 54 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Systemic Sclerosis, Small Intestinal Bacterial Overgrowth
Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis
Introduction. Autonomic dysfunction, smooth muscle fibrosis and vascular damage lead to small intestinal bacterial overgrowth (SIBO) in Systemic Sclerosis (SSc).
- Trial name
- NCT03692299
- Testing
- Saccharomyces Boulardii Oral Tablet, Metronidazole
- Where
- Mexico
- Volunteers
- 39 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Functional Dyspepsia, Small Intestinal Bacterial Overgrowth
Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia
The prevalence of functional dyspepsia (FD) is estimated to be 15% of the adult population. FD is commonly described as a condition of chronic abdominal discomfort localized to the upper abdomen.
- Conditions
- Functional Dyspepsia, Small Intestinal Bacterial Overgrowth, Chronic Abdominal Discomfort
- Trial name
- NCT00956397
- Testing
- Rifaximin, Lactulose Breath Test
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Henry C. Lin, MD
Small Intestinal Bacterial Overgrowth, Lactose Intolerance
Clinical Utility of Breath Tests in GI
Bloating, gas, pain and diarrhea are common complaints. Routine investigations are negative; these patients are labeled as IBS. In these patients, whether testing for carbohydrate malabsorption or small intestinal bacterial…
- Conditions
- Small Intestinal Bacterial Overgrowth, Lactose Intolerance, Fructose Intolerance, Glucose Intolerance
- Trial name
- NCT03261856
- Where
- United States
- Volunteers
- 1,080 people
- Sponsor
- Augusta University
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Rifaximin Therapy vs Low FODMAP Diet In IBS
Functional gastrointestinal disorders (FGIDs) are common and from the most recent global epidemiology study, an estimated 40% of the world population suffer from the condition.
- Trial name
- NCT04841980
- Testing
- Rifaximin, Low FODMAP diet
- Where
- Malaysia
- Volunteers
- 100 people
- Sponsor
- University of Malaya